Dear readers of ADxS.org, please forgive the disruption.

ADxS.org needs about $36850 in 2023. In 2022 we received donations from third parties of about $ 13870. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2023 would be over after a few days. This donation request is displayed 18,000 times a week, but only 40 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$16307 of $36850 - as of 2023-08-31
44%
I would like to donate via PayPal
More info about donations
ADxS.org Logo
ADxS.org Logo
Search Sitemap Donations Last Changes Deutsche Version
Register

Existing Account? Login

Header Image
Reboxitin for ADHD

Sitemap

The ADxS.org project
Abstract of ADxS.org
Symptoms
Consequences
Origin
Stress
Neurological aspects
Diagnostics
Prevention
Treatment and therapy
Medication for ADHD - Overview
Suitable medication for ADHD
Experimental drugs for ADHD
Sleep disorder-related medications for ADHD
Appetite stimulating drugs for ADHD
ADHD drugs in development
Less appropriate medication for ADHD
Vitamins, minerals, dietary supplements for ADHD
Plant extracts for ADHD
Medication and drugs - the difference
Substance abuse with self-medication effects in ADHD.
This and That about ADHD
Tests and surveys
Forum

Reboxitin for ADHD

Previous Page Next Page

Reboxitin is a norepinephrine reuptake inhibitor, alongside weak serotonin reuptake inhibition.

Trade names: Edronax (D, CH, A), Solcenx (D)

Reboxitin is a noradrenergic drug that has been reported to be effective in ADHD. As an antidepressant, as it was actually intended, it was probably quite unsuccessful.

The updated European Consensus on the Diagnosis and Treatment of ADHD (2018) names reboxitine as a possible alternative to atomoxetine for ADHD.1

There is evidence of efficacy of reboxitin in ADHD. However, there are only a few controlled studies.Reboxitin could be used primarily in adults without comorbidities.23

In Germany, Reboxitin is not reimbursed by health insurance companies.

  1. Kooij, Bijlenga, Salerno, Jaeschke, Bitter, Balázs, Thome, Dom, Kasper, Filipe, Stes, Mohr, Leppämäki, Brugué, Bobes, Mccarthy, Richarte, Philipsen, Pehlivanidis, Niemela, Styr, Semerci, Bolea-Alamanac, Edvinsson, Baeyens, Wynchank, Sobanski, Philipsen, McNicholas, Caci, Mihailescu, Manor, Dobrescu, Krause, Fayyad, Ramos-Quiroga, Foeken, Rad, Adamou, Ohlmeier, Fitzgerald, Gill, Lensing, Mukaddes, Brudkiewicz, Gustafsson, Tania, Oswald, Carpentier, De Rossi, Delorme, Simoska, Pallanti, Young, Bejerot, Lehtonen, Kustow, Müller-Sedgwick, Hirvikoski, Pironti, Ginsberg, Félegeházy, Garcia-Portilla, Asherson (2018): Updated European Consensus Statement on diagnosis and treatment of adult ADHD, European Psychiatrie, European Psychiatry 56 (2019) 14–34, http://dx.doi.org/10.1016/j.eurpsy.2018.11.001, Seite 23, 7.4.7. ↥

  2. Ghanizadeh (2015): A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. Nord J Psychiatry. 2015 May;69(4):241-8. doi: 10.3109/08039488.2014.972975. PMID: 25415763. REVIEW ↥

  3. Riahi, Tehrani-Doost, Shahrivar, Alaghband-Rad (2010): Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. Hum Psychopharmacol. 2010 Nov;25(7-8):570-6. doi: 10.1002/hup.1158. ↥

Previous Page Next Page